Literature DB >> 28962928

The mechanism of cone cell death in Retinitis Pigmentosa.

Peter A Campochiaro1, Tahreem A Mir2.   

Abstract

Retinitis Pigmentosa (RP) is a group of diseases in which one of a large number of mutations causes death of rod photoreceptors. After rods die, cone photoreceptors slowly degenerate in a characteristic pattern. The mechanism of rod cell death varies depending upon the gene that is mutated and the rate that rods degenerate is an important prognostic feature, because cones do not begin to degenerate until almost all rods have been eliminated. Rod cell death causes night blindness, but visual disability and blindness result from cone degeneration and therefore it is critical to determine the mechanisms by which it occurs. The death of rods reduces oxygen consumption resulting in high tissue levels of oxygen in the outer retina. The excess oxygen stimulates superoxide radical production by mismatches in the electron transport chain in mitochondria and by stimulation of NADPH oxidase activity in cytoplasm. The high levels of superoxide radicals overwhelm the antioxidant defense system and generate more reactive species including peroxynitrite which is extremely damaging and difficult to detoxify. This results in progressive oxidative damage in cones which contributes to cone cell death and loss of function because drugs or gene transfer that reduce oxidative stress promote cone survival and maintenance of function. Compared with aqueous humor samples from control patients, those from patients with RP show significant elevation of carbonyl content on proteins indicating oxidative damage and a reduction in the ratio of reduced to oxidized glutathione indicating depletion of a major component of the antioxidant defense system from ongoing oxidative stress. The first step in clinical trials will be to identify doses of therapeutic agents that reverse these biomarkers of disease to assist in design of much longer trials with functional and anatomic endpoints.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28962928     DOI: 10.1016/j.preteyeres.2017.08.004

Source DB:  PubMed          Journal:  Prog Retin Eye Res        ISSN: 1350-9462            Impact factor:   21.198


  88 in total

Review 1.  RPGR gene therapy presents challenges in cloning the coding sequence.

Authors:  Cristina Martinez-Fernandez De La Camara; Jasmina Cehajic-Kapetanovic; Robert E MacLaren
Journal:  Expert Opin Biol Ther       Date:  2019-10-20       Impact factor: 4.388

2.  The molecular chaperone sigma 1 receptor mediates rescue of retinal cone photoreceptor cells via modulation of NRF2.

Authors:  J Wang; J Zhao; X Cui; B A Mysona; S Navneet; A Saul; M Ahuja; N Lambert; I G Gazaryan; B Thomas; K E Bollinger; S B Smith
Journal:  Free Radic Biol Med       Date:  2019-02-10       Impact factor: 7.376

3.  Ciliary neurotrophic factor (CNTF) protects retinal cone and rod photoreceptors by suppressing excessive formation of the visual pigments.

Authors:  Songhua Li; Kota Sato; William C Gordon; Michael Sendtner; Nicolas G Bazan; Minghao Jin
Journal:  J Biol Chem       Date:  2018-08-16       Impact factor: 5.157

4.  GLO1 gene polymorphisms and their association with retinitis pigmentosa: a case-control study in a Sicilian population.

Authors:  Luigi Donato; Concetta Scimone; Giacomo Nicocia; Lucia Denaro; Renato Robledo; Antonina Sidoti; Rosalia D'Angelo
Journal:  Mol Biol Rep       Date:  2018-08-11       Impact factor: 2.316

5.  A Drosophila model to study retinitis pigmentosa pathology associated with mutations in the core splicing factor Prp8.

Authors:  Dimitrije Stanković; Ann-Katrin Claudius; Thomas Schertel; Tina Bresser; Mirka Uhlirova
Journal:  Dis Model Mech       Date:  2020-06-26       Impact factor: 5.758

6.  Retinal gene therapy: an eye-opener of the 21st century.

Authors:  Anne Louise Askou; Thomas Stax Jakobsen; Thomas J Corydon
Journal:  Gene Ther       Date:  2020-06-19       Impact factor: 5.250

7.  Oral N-acetylcysteine improves cone function in retinitis pigmentosa patients in phase I trial.

Authors:  Peter A Campochiaro; Mustafa Iftikhar; Gulnar Hafiz; Anam Akhlaq; Grace Tsai; Dagmar Wehling; Lili Lu; G Michael Wall; Mandeep S Singh; Xiangrong Kong
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

8.  Gene therapy for the treatment of X-linked retinitis pigmentosa.

Authors:  Cristina Martinez-Fernandez De La Camara; Anika Nanda; Anna Paola Salvetti; M Dominik Fischer; Robert E MacLaren
Journal:  Expert Opin Orphan Drugs       Date:  2018-02-27       Impact factor: 0.694

9.  Succinate Can Shuttle Reducing Power from the Hypoxic Retina to the O2-Rich Pigment Epithelium.

Authors:  Celia M Bisbach; Daniel T Hass; Brian M Robbings; Austin M Rountree; Martin Sadilek; Ian R Sweet; James B Hurley
Journal:  Cell Rep       Date:  2020-05-05       Impact factor: 9.423

10.  Locus-Level Changes in Macular Sensitivity in Patients with Retinitis Pigmentosa Treated with Oral N-acetylcysteine.

Authors:  Xiangrong Kong; Gulnar Hafiz; Dagmar Wehling; Anam Akhlaq; Peter A Campochiaro
Journal:  Am J Ophthalmol       Date:  2020-08-11       Impact factor: 5.258

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.